<DOC>
	<DOCNO>NCT00558571</DOCNO>
	<brief_summary>Primary objective : safety tolerability BI 10773 male female patient type 2 diabetes Secondary objective : pharmacokinetics pharmacodynamics BI 10773</brief_summary>
	<brief_title>4 Week Treatment With Three Oral Doses BI 10773 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Male postmenopausal hysterectomised female patient type 2 diabetes Age &gt; 18 &lt; 70 year BMI &gt; 18.5 &lt; 40 kg/m2 Antidiabetic treatment insulin glitazones one oral hypoglycaemic agent ; Fasted blood glucose &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) blood glucose level 400 mg/dl ( 22.2 mmol/L ) postprandially ; HbA1c &gt; 8.5 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>